Close Menu

NEW YORK – Personalis said Wednesday that it has priced its recently announced public offering of 6,578,947 shares of its common stock at $19 per share. It expects gross proceeds to be about $125 million.

The company, which has commercialized a suite of next-generation sequencing services for population genomics and cancer diagnostics research, didn't detail its intended use of proceeds from the offering.

BofA Securities, Citigroup and Cowen are acting as joint book-running managers. BTIG, Needham & Company and Oppenheimer & Co. are acting as co-managers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.